GSK agreed to acquire ex-China rights to Hutchmed’s HMPL-A830 under a deal reported as worth up to $1.295 billion, including a $110 million upfront payment and potential development and regulatory milestones. The preclinical asset is an antibody-targeted therapy conjugate designed to deliver a KRAS inhibitor payload to EGFR-expressing tumors while blocking both EGFR and KRAS signaling. GSK’s initial clinical development plan focuses on colorectal, pancreatic, and lung cancer, with the trial expected to begin in the second half of 2026. Hutchmed will retain rights for Mainland China, Hong Kong, Macau, and Taiwan and will oversee global Phase 1 development, while GSK is set to manage later-stage development and commercialization in licensed territories. For the biotech industry, the agreement is another move by large pharma to broaden oncology modality depth through antibody-drug conjugate-adjacent architectures and pipeline externalization. It also signals how KRAS targeting remains a priority area for sponsors willing to finance early preclinical risk.